Table 2.
Baseline characteristics of 134 Parkinson's disease patients in relation to COMT Val158Met‐ and DRD2 C957T genotype
| Variable | COMT 158Met/Met genotype (n = 42) | COMT 158Val/Met genotype (n = 64) | COMT 158Val/Val genotype (n = 26) | P‐value |
|---|---|---|---|---|
| Age | 70.3 (9.0) | 69.3 (10.3) | 72.9 (9.1) | .273 |
| Disease duration in months, median (IQR) | 25.4 (12.6‐36.1) | 13.4 (8.1‐24.4) | 16.9 (10.0‐35.3) | .042 |
| Sex, M:F (% male) | 23:19 (54.8%) | 41:23 (64.1%) | 15:11 (57.7%) | .614 |
| UPDRS III, median (IQR) | 26 (13‐36) | 25 (18‐34) | 29 (24‐37) | .340 |
| MMSE | 28.6 (1.4) | 28.7 (1.4) | 28.7 (1.3) | .959 |
| CSF NFL concentration, ng/L, [number with baseline sample] | 1247 (760) [32] | 1499 (1601) [45] | 1508 (738) [18] | .638 |
| Variable | DRD2 957C/C genotype (n = 31) | DRD2 957T/C genotype (n = 66) | DRD2 957T/T genotype (n = 37) | P‐value |
|---|---|---|---|---|
| Age | 71.9 (9.7) | 69.1 (10.2) | 71.5 (9.3) | .286 |
| Disease duration in months, median (IQR) | 24.0 (10.2‐41.0) | 12.7 (8.0‐30.0) | 20.6 (12.2‐31.0) | .138 |
| Sex, M:F (% male) | 18:13 (58.1%) | 40:26 (60.6%) | 22:15 (59.5%) | .971 |
| UPDRS III, median (IQR) | 28 (21‐35) | 23 (16‐31) | 26 (19‐39) | .166 |
| MMSE | 28.5 (1.6) | 28.8 (1.3) | 28.4 (1.6) | .377 |
| CSF NFL concentration, ng/L, [number with baseline sample] | 1465 (762) [23] | 1269 (848) [50] | 1762 (1928) [27] | .247 |
Values are expressed as means (standard deviation) unless otherwise stated. Disease duration was defined by time from onset of first motor symptom to diagnosis of PD. COMT, catechol‐O‐methyltransferase; DRD2, dopamine receptor D2; PD, Parkinson's disease; IQR, interquartile range; UPDRS III, Unified Parkinson's Disease Rating Scale, part III (motor function); MMSE, Mini‐Mental State Examination; CSF, cerebrospinal fluid; NFL, neurofilament light chain protein.